Takeda Pharmaceutical Company Limited Share Price
Stocks
4502
JP3463000004
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Japan Exchange
07:30:00 09/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 5,615.00 JPY | -2.52% |
|
-3.59% | +16.13% |
| 09-08 | Pharvaris' genetic disorder drug meets main goal in late-stage trial | RE |
| 09-04 | After obesity, pharma seeks its next mega-blockbuster in sleep |  |
| Market Cap | 9,197B 59.65B 51.28B 48.25B 44.03B 82.17B 5,655B 82.59B 572B 221B 2,890B 224B 219B | P/E 2027 * |
45.6x | P/E 2028 * | 29x |
|---|---|---|---|---|---|
| Enterprise Value | 13,104B 84.98B 73.07B 68.74B 62.73B 117B 8,056B 118B 814B 315B 4,118B 319B 312B | EV / Sales 2027 * |
2.79x | EV / Sales 2028 * | 2.7x |
| Free-Float |
99.26% | Yield 2027 * |
3.55% | Yield 2028 * | 3.62% |
| Markets | Quality | ||
|---|---|---|---|
Japan Exchange
| 4502 | Delayed | |
OTC Markets
| TKPHF | Delayed | |
|
Tradegate
| TKD | Real-time | |
|
Boerse Muenchen
| TKD | Real-time | |
|
Deutsche Boerse AG
| TKD | Delayed | |
|
Börse Stuttgart
| TKD | Delayed | |
|
Wiener Boerse
| TKD | End-of-day quote |
Last Transcript : Takeda Pharmaceutical Company Limited
| 1 day | -2.52% | ||
| 1 week | -3.59% | ||
| Current month | -2.60% | ||
| 1 month | +0.59% | ||
| 3 months | +12.86% | ||
| 6 months | -0.04% | ||
| Current year | +16.13% |
| 1 week | 5,615 |  | 5,917 |
| 1 month | 5,482 | | 5,917 |
| Current year | 4,710 | | 6,033 |
| 1 year | 4,102 | | 6,033 |
| 3 years | 3,852 | | 6,033 |
| 5 years | 2,993 | | 6,033 |
| 10 years | 2,894.5 | | 6,693 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 31/12/2024 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 31/03/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 47 | 31/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 60 | 31/05/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 31/12/2018 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 31/05/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 02/09/26 | Sell | Chief Technology Officer | -116,191 | 0.0073% | ||
| 19/08/26 | Sell | Chief Technology Officer | -19,651 | 0.0012% | ||
| 18/08/26 | Sell | Head of Human Resources | -12,980 | 0.0008% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.52% | -3.59% | +24.42% | +23.54% | 59.65B | |
| -2.21% | -3.11% | +52.16% | +91.64% | 1,002B | |
| -2.22% | -0.76% | +51.08% | +67.61% | 649B | |
| -2.99% | -4.31% | +18.59% | +66.94% | 440B | |
| -0.29% | +0.29% | +29.85% | +37.93% | 346B | |
| -0.29% | -14.94% | +9.45% | +26.49% | 263B | |
| -0.67% | -1.19% | -1.19% | +12.68% | 250B | |
| -10.08% | -10.26% | +40.32% | +51.55% | 213B | |
| -0.87% | -3.60% | -14.14% | -57.48% | 201B | |
| -2.88% | -2.19% | +26.54% | +92.95% | 182B | |
| Average | -1.67% | -2.00% | +23.71% | +41.39% | 360.33B | |
| Weighted average by Cap. | -0.68% | -2.37% | +32.77% | +57.18% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,701B 30.49B 26.21B 24.66B 22.5B 42B 2,890B 42.21B 292B 113B 1,477B 114B 112B | 4,781B 31.01B 26.66B 25.08B 22.89B 42.72B 2,940B 42.94B 297B 115B 1,503B 116B 114B |
| Net income | 196B 1.27B 1.1B 1.03B 941M 1.76B 121B 1.76B 12.21B 4.73B 61.75B 4.79B 4.68B | 322B 2.09B 1.8B 1.69B 1.54B 2.88B 198B 2.9B 20.04B 7.75B 101B 7.85B 7.68B |
| Net Debt | 3,907B 25.33B 21.78B 20.49B 18.7B 34.9B 2,402B 35.08B 243B 93.94B 1,228B 95.13B 93.05B | 3,702B 24.01B 20.64B 19.42B 17.72B 33.07B 2,276B 33.25B 230B 89.03B 1,163B 90.16B 88.19B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/09/26 | JP¥5,615.00 | -2.52% | 5,530,300 |
| 08/09/26 | JP¥5,760.00 | -0.29% | 2,467,300 |
| 07/09/26 | JP¥5,777.00 | +0.42% | 2,396,900 |
| 04/09/26 | JP¥5,753.00 | -2.62% | 5,384,700 |
| 03/09/26 | JP¥5,908.00 | +1.44% | 3,253,000 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
Select your edition
All financial news and data tailored to specific country editions
